首页 > 市场调查报告书 > 製药

再生医学细胞疗法

北美T 细胞治疗市场预测至2030 年- 区域分析- 按模式（研究和商业化）、治疗类型[CAR T 细胞疗法和基于T 细胞受体(TCR) 的] 和适应症（血液恶性肿瘤和实体瘤）

市场调查报告书

商品编码

1452634

北美T 细胞治疗市场预测至2030 年- 区域分析- 按模式（研究和商业化）、治疗类型[CAR T 细胞疗法和基于T 细胞受体(TCR) 的] 和适应症（血液恶性肿瘤和实体瘤）

North America T Cell Therapy Market Forecast to 2030 - Regional Analysis - by Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], and Indication (Hematologic Malignancies and Solid Tumors)

出版日期: 2024年01月15日 | 出版商:

The Insight Partners | 英文 70 Pages | 订单完成后即时交付

价格

简介目录图表

2022年北美T细胞治疗市值为16.4552亿美元，预计2030年将达到53.2975亿美元；预计2022年至2030年CAGR为15.8%。

T 细胞治疗批准数量的增加推动了北美 T 细胞治疗市场的发展

细胞疗法的优点包括标靶治疗、更快、更有效的恢復以及减少副作用。由于 FDA 批准的产品的可用性，细胞疗法在全球范围内被广泛采用。以下是近年来FDA批准的T细胞治疗产品清单：

例如，2022年6月，百时美施贵宝的Breyanzi (lisocabtagene maraleucel) 获得FDA 批准，这是一种CD19 定向嵌合抗原受体(CAR) T 细胞疗法，用于治疗成人大B 细胞淋巴瘤(LBCL ) 患者。

2022年2月，美国食品药物管理局(FDA) 批准Yescarta (axicabtagene ciloleucel) CAR T 细胞疗法用于治疗一线化学免疫疗法难治或一线化学免疫疗法12 个月内復发的大B 细胞淋巴瘤成人患者。 Yescarta 是第一个获得全国综合癌症网络 (NCCN) 1 类推荐的 CAR T 细胞疗法。

2022年2月，FDA核准了ciltacabtagene autoleucel（商品名CARVYKTI）用于治疗经过四线或四线以上治疗（包括蛋白酶体抑制剂、免疫调节剂和抗CD38单株抗体）后復发或难治性多发性骨髓瘤的成年患者。

2022年1月，FDA核准Kimmtrak（tebentafusp-tebn）用于治疗HLA-A*02:01阳性的不可切除或转移性葡萄膜黑色素瘤患者。

2021年3月，Abecma（idecabtagene vicleucel）被FDA核准用于治疗復发或难治性多发性骨髓瘤。该疗法是一种针对 B 细胞成熟抗原 (BCMA) 的转基因自体 T 细胞免疫疗法，适用于治疗患有难治性多发性骨髓瘤的成年患者。

因此，越来越多的 T 细胞疗法获批正在推动北美 T 细胞疗法市场的成长。

北美T细胞治疗市场概况

北美的 T 细胞治疗市场分为美国、加拿大和墨西哥。到2022 年，美国在该地区占据最大的市场份额，并且由于癌症和自体免疫疾病等慢性疾病负担的增加、研发活动的增长以及强大而成熟的市场份额，预计将在预测期内继续占据主导地位。市场参与者。此外，随着 CAR T 细胞疗法临床研究的增加，北美市场预计在预测期内将会成长。据CDC称，2020年美国报告了1,603,844例新癌症病例，602,347人死亡。预计2023年美国将有184,720人被诊断出患有白血病、淋巴瘤或骨髓瘤。

Tisagenlecleucel（KymriahTM，Novartis，Morris Plains，新泽西州，美国）和axicabtagene ciloleucel（YescartaTM，Gilead Sciences Canada，El Segundo，CA，US）是加拿大卫生部于2018 年在加拿大批准的首批两种商业化CAR TCAR T细胞。分别为2019年。两者都是第二代抗 CD19 CAR T 细胞，被批准用于患有 r/r DLBCL、原发性纵隔 B 细胞淋巴瘤和转化滤泡性淋巴瘤的成年患者。此外，加拿大主导的癌症免疫疗法-01 (CLIC-01) 是加拿大第一个引入 CAR T 细胞疗法的计画。它使用不同类型的细胞製造技术，提供更便宜、更公平的治疗。自2022 年3 月起，位于哈利法克斯的伊丽莎白女王二世健康科学中心成为加拿大大西洋地区第一个在本地提供CAR T 细胞治疗的机构。在此之前，被推荐接受这种高度个人化癌症药物的新斯科细亚省患者必须前往境外旅行。国家接受治疗。该计划的实现得益于政府每年 670 万美元的投资。因此，不断增加的癌症病例和政府的措施推动了北美 T 细胞治疗市场的发展。

北美 T 细胞治疗市场收入及 2030 年预测（百万美元）

北美T细胞治疗市场细分

北美 T 细胞治疗市场分为模式、治疗类型、适应症和国家。

根据模式，北美 T 细胞治疗市场分为研究和商业化。 2022年，商业化细分市场将占据更大的市场份额。

根据治疗类型，北美T细胞治疗市场分为CAR T细胞疗法和T细胞受体（TCR）疗法。 2022年，CAR T细胞疗法领域将占据更大的市场份额。

根据适应症，北美 T 细胞治疗市场分为血液恶性肿瘤和实体肿瘤。 2022 年，血液恶性肿瘤细分市场占据最大市场。

根据国家/地区，北美 T 细胞治疗市场分为美国、加拿大和墨西哥。 2022年，美国在北美T细胞治疗市场占有率中占据主导地位。

Bluebird Bio Inc、Bristol-Myers Squibb Co、Cartesian Therapeutics Inc、Gilead Sciences Inc、Innovent Biologics Inc、Janssen Global Services LLC 和 Novartis AG 是北美 T 细胞治疗市场的一些领先公司。

In February 2022, the US Food and Drug Administration (FDA) approved Yescarta (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first line chemoimmunotherapy or that relapses within 12 months of first line chemoimmunotherapy. Yescarta is the first CAR T-cell therapy to receive a National Comprehensive Cancer Network (NCCN) Category 1 recommendation.

In February 2022, the FDA approved ciltacabtagene autoleucel (brand name CARVYKTI) for treating adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

In January 2022, the FDA approved Kimmtrak (tebentafusp-tebn) for treating unresectable or metastatic uveal melanoma patients who are HLA-A*02:01 positive.

In March 2021, Abecma (idecabtagene vicleucel) was approved by the FDA for treating relapsed or refractory multiple myeloma. The treatment is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T-cell immunotherapy indicated for treating adult patients with refractory multiple myeloma.

Therefore, the increasing number of approvals for T-cell therapies is fueling the North America T cell therapy market growth.

North America T Cell Therapy Market Overview

The T-cell therapy market in North America is segmented into the US, Canada, and Mexico. In 2022, the US held the largest market share in this region and is expected to continue its dominance during the forecast period due to the increasing burden of chronic disorders such as cancer and autoimmune disorders, growth in research and development activities, and strong and established market players. Also, with an increase in clinical studies in CAR T-cell therapies, the market in North America is expected to grow during the forecast period. According to CDC, 1,603,844 new cancer cases were reported and 602,347 people died in the US in 2020. An estimated 184,720 people in the US will be diagnosed with leukemia, lymphoma, or myeloma in 2023.

Tisagenlecleucel (KymriahTM, Novartis, Morris Plains, NJ, US) and axicabtagene ciloleucel (YescartaTM, Gilead Sciences Canada, El Segundo, CA, US) were the first two CAR T-cells commercially available and approved in Canada by Health Canada in 2018 and 2019, respectively. Both are second-generation anti-CD19 CAR T-cells, approved for adult patients with r/r DLBCL, primary mediastinal B-cell lymphoma, and transformed follicular lymphoma. Moreover, Canadian-Led Immunotherapies in Cancer-01 (CLIC-01) is the first to introduce CAR T-cell therapy in Canada. It uses a different kind of cell manufacturing that unveils less expensive and more equitable treatment. The Queen Elizabeth II Health Sciences Centre in Halifax became the first facility in Atlantic Canada to offer CAR T-cell therapy locally as of March 2022. Prior to this, Nova Scotia patients who were recommended for this highly personalized cancer medicine had to travel outside the country to receive the treatment. The program was made possible with a government investment of US$ 6.7 million annually. Thus, the rising cancer cases and initiative by the government fuel the T-cell therapy market in North America.

North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)

North America T Cell Therapy Market Segmentation

The North America T cell therapy market is segmented into modality , therapy type, indication, and country.

Based on modality, the North America T cell therapy market is bifurcated into research and commercialized. The commercialized segment held a larger market share in 2022.

Based on therapy type, the North America T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held a larger market share in 2022.

Based on indication, the North America T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held the largest market share in 2022.

Based on country, the North America T cell therapy market is segmented into the US, Canada, and Mexico. The US dominated the North America T cell therapy market share in 2022.

Bluebird Bio Inc, Bristol-Myers Squibb Co, Cartesian Therapeutics Inc, Gilead Sciences Inc, Innovent Biologics Inc, Janssen Global Services LLC, and Novartis AG are some of the leading companies operating in the North America T cell therapy market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 North America T Cell Therapy Market, by Country (US$ Million)

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America T Cell Therapy Market - Key Industry Dynamics

4.1 Market Drivers:
- 4.1.1 Growing Burden of Cancer Worldwide
- 4.1.2 Increasing Number of T-Cell Therapy Approvals
4.2 Market Restraints
- 4.2.1 Side-effects of CAR T-Cell Therapy
4.3 Market Opportunities
- 4.3.1 Growing Investment in T-Cell Therapy
4.4 Future Trends
- 4.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
4.5 Impact Analysis:

5. T Cell Therapy Market - North America Market Analysis

5.1 North America T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030

6. North America T Cell Therapy Market - Revenue and Forecast to 2030 - by Modality.

6.1 Overview
6.2 North America T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
6.3 Research
- 6.3.1 Overview
- 6.3.2 Research: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Commercialized
- 6.4.1 Overview
- 6.4.2 Commercialized: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

7. North America T Cell Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

7.1 Overview
7.2 North America T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
7.3 CAR T-cell Therapy
- 7.3.1 Overview
- 7.3.2 CAR T-cell Therapy: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 T-cell Receptor (TCR)-based.
- 7.4.1 Overview
- 7.4.2 T-cell Receptor (TCR)-based: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

8. North America T Cell Therapy Market - Revenue and Forecast to 2030 - by Indication.

8.1 Overview
8.2 North America T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
8.3 Hematologic Malignancies
- 8.3.1 Overview
- 8.3.2 Hematologic Malignancies: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- 8.3.3 North America T Cell Therapy Market, by Haematological Malignancies, 2020-2030 (US$ Million)
8.4 Solid Tumor
- 8.4.1 Overview
- 8.4.2 Solid Tumor: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. North America T Cell Therapy Market - Country Analysis

9.1 Overview

10. T Cell Therapy Market-Industry Landscape

10.1 Overview
10.2 Growth Strategies in T Cell Therapy Market
10.3 Organic Growth Strategies
- 10.3.1 Overview
10.4 Inorganic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Legend Biotech Corp
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Janssen Global Services LLC
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Gilead Sciences Inc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Bristol-Myers Squibb Co
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Novartis AG
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Cartesian Therapeutics Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Innovent Biologics Inc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms

简介目录图表

List Of Tables

Table 1. North America T Cell Therapy Market Segmentation
Table 2. North America T Cell Therapy Market, by Hematological Malignancies - Revenue and Forecast to 2030 (US$ Million)
Table 3. US: North America T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 4. US: North America T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 5. US: North America T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 6. US: North America T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 7. Canada: North America T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 8. Canada: North America T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 9. Canada: North America T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 10. Canada: North America T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 11. Mexico: North America T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 12. Mexico: North America T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 13. Mexico: North America T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 14. Mexico: North America T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 15. Recent Organic Growth Strategies in T Cell Therapy Market
Table 16. Recent Inorganic Growth Strategies in the T Cell Therapy Market
Table 17. Glossary of Terms, North America T Cell Therapy Market

List Of Figures

Figure 1. North America T Cell Therapy Market Segmentation, By Country
Figure 2. North America T Cell Therapy Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030
Figure 5. North America T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
Figure 6. Research: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Commercialized: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. North America T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
Figure 9. CAR T-cell Therapy: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. T-cell Receptor (TCR)-based: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. North America T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
Figure 12. Hematologic Malignancies: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Solid Tumor: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. North America T Cell Therapy Market, by Key Country - Revenue (2022) (US$ Million)
Figure 15. North America T Cell Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 16. US: North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 17. Canada: North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 18. Mexico: North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 19. Growth Strategies in T Cell Therapy Market